HUTCHMED (China) Ltd (STU:H7T1)
€ 15.7 0 (0%) Market Cap: 2.68 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 4.10 GF Score: 70/100

HUTCHMED (China) Ltd and Epizyme Inc Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® in Greater China Call Transcript

Aug 09, 2021 / 01:30PM GMT
Release Date Price: €34.6 (-3.35%)
Operator

Welcome to the HUTCHMED Company Update. I will now hand the session to Mr. Christian Hogg, CEO of HUTCHMED, to begin today's presentation.

Christian Lawrence Hogg;China;Limited;Former CEO;Executive Director
HUTCHMED

()-&

Okay. Thanks very much, Mark. So welcome, everybody, to the presentation today to talk about the strategic collaboration that we've just signed with Epizyme with regards to TAZVERIK. The plan today is that we have myself, Dr. Wei-Guo Su, our Chief Scientific Officer; and Mark Lee, our Senior VP, Corporate Finance and Development on the line. But the plan is to spend maybe 20 minutes to take you through the deal and our plans and then open it up for Q&A for maybe another 20 minutes after that. So a relatively short call today unless there's an extended set of questions.

What we're going to cover here on Page #3 is the overview of the transaction, a little bit of background on TAZVERIK for those analysts or investors that -- of ours that have not had much exposure to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot